Global Study of Del-desiran for the Treatment of DM1
This study, called the Global Study of Del-desiran, is looking at a new treatment for Myotonic Dystrophy Type 1 (DM1), also known as Steinert's disease. Researchers want to find out if the medicine, named del-desiran, is safe and effective in improving this condition. Participants will be randomly assigned to receive either del-desiran or a placebo (a treatment with no active medicine) through an IV drip every eight weeks for about a year. Doctors and patients won't know who is getting which treatment. The study will last around 60 weeks in total. Afterwards, there might be an option to continue receiving the medicine in a long-term study, if approved.
A colpo d'occhio
Di cosa tratta questo studio?
Myotonic Dystrophy Type 1 (DM1), sometimes called Steinert's disease, is a condition that affects muscles, causing them to weaken and have trouble relaxing after use. This can impact many daily activities. Currently, there isn't a cure, and treatments mainly help manage the symptoms. This study aims to see if a new investigative medicine, called del-desiran, could be a helpful treatment for people living with DM1.
This is a 'Phase 3' study, which means it's one of the final stages of testing a new medicine before it might be considered for wider use. It's designed to be 'randomised', meaning participants are put into groups by chance, and 'double-blind', meaning neither the patient nor the doctor knows if they're receiving the new medicine or a placebo (a dummy treatment). This helps ensure the study results are as fair and accurate as possible.
The main goal of this research is to see if del-desiran is safe for people with DM1 and if it can improve their symptoms or slow the progression of the disease. An independent group of experts will regularly check on the study's progress to make sure everyone is safe.
Punti chiave
- Tests a new medicine (del-desiran) for Myotonic Dystrophy Type 1 (DM1).
- Compares the medicine to a placebo (dummy treatment).
- Participation involves IV infusions every 8 weeks for about a year.
- Aims to check if del-desiran is safe and effective.
- For adults aged 16-65 who can walk independently.
- You won't know if you're getting the active drug or placebo.
Chi può essere idoneo?
This study is looking for adults aged 16 to 65 who have an official diagnosis of Myotonic Dystrophy Type 1 (DM1), confirmed by genetic testing. You also need to be able to walk by yourself, even if you use aids like ankle braces, for at least 10 metres.
There are also some reasons why you might not be able to join. For example, if you are pregnant, breastfeeding, or planning to become pregnant during the study. You also can't take part if you have serious uncontrolled diabetes, certain heart conditions, or if you've recently taken other experimental medicines.
Questo studio potrebbe fare al caso tuo?
Rispondi a queste domande rapide per vedere se potresti essere idoneo. Questo è solo una guida — il team di ricerca prende la decisione finale.
- Do I have a confirmed diagnosis of Myotonic Dystrophy Type 1 (DM1)?
- Am I between 16 and 65 years old?
- Can I walk on my own for at least 10 metres, even with walking aids?
- Am I not pregnant, breastfeeding, or planning to become pregnant while in the study?
- Do I have generally stable health conditions?
Cosa comporta la partecipazione?
If you join this study, you'll first have a screening period that could last up to six weeks to check if you're suitable. The treatment part of the study will then last about 54 weeks. Overall, your involvement will be for around 60 weeks, which is a bit over a year.
During the treatment period, you'll visit the study site every eight weeks to receive either del-desiran or a placebo through an IV drip. You'll receive a total of seven doses, with the last one at Week 48. There will be a final check-up at Week 54. After this, if you meet the requirements and it's approved, you might have the option to join a long-term study where everyone receives the active medicine.
Rischi e benefici potenziali
Locations (34)
- Stanford UniversityCodice postale verificatoStanford, United States
- University of ColoradoCodice postale verificatoDenver, Stati Uniti
- University of FloridaCodice postale verificatoGainesville, Stati Uniti
- University Research Center of South FloridaCodice postale verificatoTampa, Stati Uniti
- Indiana University (IU)Codice postale verificatoIndianapolis, Stati Uniti
- Kansas University Medical CenterCodice postale verificatoKansas City, Stati Uniti
- Kennedy Krieger InstituteCodice postale verificatoBaltimora, Stati Uniti
- Beth Israel Deaconess Medical CenterCodice postale verificatoBoston, Stati Uniti
- University of MinnesotaCodice postale verificatoMinneapolis, Stati Uniti
- Centro Medico dell'Università di RochesterCodice postale verificatoRochester, Stati Uniti
- Duke University Medical CenterCodice postale verificatoDurham, Stati Uniti
- Wake ForestCodice postale verificatoWinston-Salem, Stati Uniti
Domande comuni
What is Myotonic Dystrophy Type 1 (DM1)?
DM1 is a genetic condition that causes muscles to become weak and have difficulty relaxing. It can affect many parts of the body.
What is a 'placebo'?
A placebo is a dummy treatment that looks exactly like the real medicine but contains no active ingredients. It's used to compare against the new medicine.
Will I know if I'm getting the drug or placebo?
No, this is a 'double-blind' study, meaning neither you nor your doctors will know if you're receiving del-desiran or the placebo until after the study ends.
How often do I need to visit the clinic?
After screening, you'll need to visit the clinic every eight weeks for IV infusions, for a total of seven doses, and a final check-up.
What happens after the study finishes?
After 54 weeks, if you meet certain criteria and it's allowed, you might have the option to join a separate long-term study where you would receive the active medicine.
Come saperne di più
Parla sempre con il tuo medico di base o specialista prima di decidere di partecipare a uno studio.
Discussione
Discussione della comunità
Supportato dal nostro forum su community.patient.info. Si prega di essere rispettosi — questo non è un consiglio medico.